Connect with us
Sanofi seeks a buyer for its consumer healthcare division, valued at around 20 billion euros, with offers due by mid-July. Interested parties include Advent International, PAI...
Sanofi acquires 4.9% of Novavax shares for $70 million, doubling the latter's valuation to around $1.4 billion. This investment is part of a co-exclusive licensing agreement...
With the transaction, Sanofi will assume and repay Inhibrx's outstanding third-party debt and will finance New Inhibrx with $200 million in cash (€183 million) and retain...
Within the health sector, 20% of investment in R&D came from the ten largest companies by investment, which allocated €53.9 billion, €10 billion more than the...
Paris-based Aqemia will receive upfront and milestone payments under the deal that will be used to deepen R&D. In addition, it plans to double its workforce...
This year, one of the main headaches for managers in the sector will be inflation. GSK and Novartis plan to carry out a double-digit price increase...
After a relatively lackluster 2021, Amgen was looking for a second wind. The laboratory was only able to survive last year thanks to its collaboration with...
The French pharmaceutical group Sanofi explained that the price expectations of the target did not match its criteria. Some analysts had a mixed opinions on this...
Novartis has the worst rating in the European pharmaceutical industry, while AstraZeneca downgrades its expectations from exceptional to neutral. Credit Suisse has also analyzed the Spanish...
Immuno-oncology and molecular oncology are two of Sanofi's most promising bets to tackle some of the most difficult-to-treat cancers. While immuno-oncology research is focused on finding...